IVERIC bio Reports Third Quarter 2019 Operational Highlights and Financial Results
– Conference Call and Webcast Today, November 12, 2019, at 8:00 a.m. ET – NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq:…
Pharmaceuticals, Biotechnology and Life Sciences
– Conference Call and Webcast Today, November 12, 2019, at 8:00 a.m. ET – NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq:…
LONDON–(BUSINESS WIRE)–#IndirectSpendAnalysis–SpendEdge, a leading provider of procurement market intelligence solutions, has announced the completion of their latest article on the…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided…
On Track for Anticipated Initiation of BLA Submission in December, 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN), a late-stage clinical…
CAMBRIDGE, Mass. & MENLO PARK, Calif.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they…
– Company Plans to Use Previously Announced Positive Zimura Clinical Trial as One of Two Pivotal Trials – – Zimura…
– Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – – GB1275 granted Orphan Drug…
Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites Expanded the DEXTENZA® Field Team by 50% Implemented…
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…
— Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and…